Log in to your Inderes Free account to see all free content on this page.

NeoDynamics

Less than 1K followers

NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden.

Coverage

Claus Thestrup

CEO, Sweden

Latest research

Latest analysis report

Released: 22.12.2022

All

Research

Webcasts

Press releases

ShowingAll content types

Press release7/30/2024, 9:00 AM

Last day of trading at Nasdaq First North

Regulatory press release7/12/2024, 6:59 AM

Unofficial trading through Pareto Securities after delisting

Regulatory press release7/3/2024, 8:15 AM

NeoDynamics terminates the agreement with liquidity provider

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release7/2/2024, 11:48 AM

NeoDynamics' stock is delisted from Nasdaq First North

Regulatory press release6/20/2024, 4:00 PM

NeoDynamics applies for delisting

Regulatory press release6/17/2024, 3:45 PM

Bulletin from the annual general meeting in NeoDynamics AB (publ)

Regulatory press release6/4/2024, 8:00 PM

Update on NeoDynamics’ financial situation

Regulatory press release5/15/2024, 7:55 PM

NOTICE OF ANNUAL GENERAL MEETING IN NEODYNAMICS AB (PUBL)

Regulatory press release5/15/2024, 7:45 PM

NeoDynamics intends to apply for delisting

Regulatory press release5/7/2024, 6:45 AM

NeoDynamics Interim Report Jan-March 2024

Regulatory press release5/1/2024, 6:00 AM

NeoDynamics publishes Annual Report 2023

Press release4/25/2024, 2:30 PM

Update on NeoDynamics’ management team

Press release4/15/2024, 6:45 AM

Salénterprise increases its shareholding in NeoDynamics.

Regulatory press release4/4/2024, 9:30 AM

NeoDynamics announces the final outcome regarding the exercise warrants of series TO3

Regulatory press release3/22/2024, 7:45 AM

Update on NeoDynamics’ Management Team

Regulatory press release3/20/2024, 7:45 AM

NeoDynamics announces outcome of RIghts issue of shares

HCA Biosnack update: Biotech and Life Science stocks outperform as the general stock market moves to record highs.

Analyst Comment3/14/2024, 8:36 AM by

Henrik Ekman, Philip Coombes, Claus Thestrup

HCA Biosnack update: Biotech and Life Science stocks outperform as the general stock market moves to record highs.

After a slow start to 2024, February and the beginning of March turned out to be a very strong period for Biotech and Life Science stocks as illustrated above. Even more so, if measured since late October 2023. Looking at 2024, the general S&P Biotech index is now up 7.7 percent year-to-date, outperforming MSCI World All Countries which is up 7.0 percent. Nordic focused HCA Little Mermaid index is up 6.0 percent.

Ascelia Pharma BioPorto Curasight ExpreS2ion Biotech Holding FluoGuide NeoDynamics Pharma Equity Group Qlife Holding

Regulatory press release3/7/2024, 7:45 AM

NeoDynamics announces the preliminary outcome of the exercise of warrants of series TO3.

Regulatory press release2/29/2024, 12:00 PM

Update on NeoDynamics’ Management Team

Regulatory press release2/29/2024, 8:40 AM

Correction of press release: NeoDynamics publishes information memorandum in connection with the forthcoming rights issue

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.